Antengene Bags Thailand FDA Approval To commercialize Xpovio

Antengene Corporation Limited, a top creative, internationally-operating biopharmaceutical company focused on finding, creating, and selling top-of-the-line medications for cancer, revealed that the Thailand Food and Drug Administration has given the green light to a New Drug Application (NDA) for Xpovio (selinexor).

Two signs are for the treatment of adult patients with multiple myeloma (MM): one is with bortezomib and dexamethasone after one prior therapy, and the other is with dexamethasone after four prior therapies and refractory disease. The latter must have shown progression on the last therapy and resistance to specific types of drugs.

Featuring a unique way of working, Xpovio is the first orally-available, selective XPO1 inhibitor in the world, and has been approved in nine APAC markets. The approval of Xpovio in Thailand will bring new treatments to the medical care of MM patients in the country, benefiting numerous patients and their families. As of now, Xpovio has also been incorporated into national healthcare insurance or reimbursement programs in China, Australia, Singapore, and South Korea.

The ASEAN area, known for its consistent economic expansion and a population of over 600 million, has emerged as a key market opportunity for worldwide biomedical progress. The rising number of elderly people in ASEAN has raised the total burden of diseases on individuals and communities, resulting in a greater need for new treatments.